- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
API Nanotronics Corp. (OTCBB: APIO) ("API" or the "Company"), a leading supplier of electronic components to the defense and communications sectors, announced today that it has received over $2 million in new contracts.
These contracts include orders for API's Filtran Ltd. subsidiary totaling $600,000 for transformers, inductors and filters used in a variety of military and government radio communication systems and a 2 year blanket award of $1.8 million won by API's Keytronics Inc. subsidiary providing transformers, chokes, inductors, capacitor networks, to a leading defense company. Keytronics has also recently gained approval on 4 qualification items for the "787 Dreamliner Program" at Goodrich Aerospace, and the Airbus project, which is a 12-15 year program.
Phillip DeZwirek, Chairman and CEO of API, stated, "These new orders are substantial and speak to continued momentum in our core business. While we pursue our goal of advancing next generation products through nanotechnology, it is important to recognize the strength and consistency of our traditional business."
About API Nanotronics
API Nanotronics Corp. through its wholly owned subsidiaries API Electronics Inc., National Hybrid Inc., Filtran Group, TM Systems and Keytronics, is engaged in the manufacture of electronic components and systems for the defense and communications industries. With a growing list of blue chip customers, including Honeywell/Allied Signal, General Dynamics, Lockheed Martin, and numerous other top technology-based firms around the world, API regularly ships off-the-shelf and custom designed products to clients in more than 34 countries. API owns state-of-the-art manufacturing and technology centers in New York, Connecticut and Ontario, Canada and has manufacturing capabilities in China and a distribution center in Britain. API Nanotronics trades on the OTC Bulletin Board under the symbol APIO. For further information, please visit the company website at http://www.apinanotronics.com
Safe Harbor for Forward-Looking Statements:
Except for statements of historical fact, the information presented herein constitutes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include general economic and business conditions, the ability to acquire and develop specific projects, the ability to fund operations and changes in consumer and business consumption habits and other factors over which API Nanotronics Corp. and its subsidiaries and affiliates have little or no control.
ON BEHALF OF THE BOARD
API Nanotronics Corp.
Philip DeZwirek, CEO
For more information, please click here
Bakerview Investor Relations, Inc.
Copyright © Market WireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Lithium battery catalyst found to harm key soil microorganism February 7th, 2016
Discovery of the specific properties of graphite-based carbon materials February 6th, 2016
Scientists guide gold nanoparticles to form 'diamond' superlattices: DNA scaffolds cage and coax nanoparticles into position to form crystalline arrangements that mimic the atomic structure of diamond February 4th, 2016
Scientists build a neural network using plastic memristors: A group of Russian and Italian scientists have created a neural network based on polymeric memristors -- devices that can potentially be used to build fundamentally new computers January 28th, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015